Biblio
. .
CD3/CD19 depleted matched and mismatched unrelated donor hematopoietic stem cell transplant with targeted T cell addback is associated with excellent outcomes in pediatric patients with non-malignant hematologic disorders. Biol Blood Marrow Transplant. 2018.
. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2014;371(16):1507-1517.
Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transpl. Biol Blood Marrow Transplant. 2018.
Cytokine Release Syndrome after Haplo-Identical Stem Cell Transplant. Biol Blood Marrow Transplant. 2016.
. A day 14 endpoint for acute GVHD clinical trials. Transplant Cell Ther. 2024.
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019;322(8):746-755.
Exagamglogene Autotemcel for Severe Sickle Cell Disease. N Engl J Med. 2024.
In vivo hematopoietic stem cell modification by mRNA delivery. Science. 2023;381(6656):436-443.
INSPIRED Symposium Part 5: Expanding the Use of CAR T cells in Children and Young Adults. Transplant Cell Ther. 2024.
. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019;3(23):4034-4042.
Partially CD3-depleted unrelated and haploidentical donor PSCT has favorable GVHD and survival rates in pediatric hematologic malignancy. Biol Blood Marrow Transplant. 2019.